Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart Elborn

Showing results (191-200 of 270) with videos related to

Pageof 27
Sort By:
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 14, 2011
Ancestral haplotype 8.1 and lung disease severity in European cystic fibrosis patientsHarriet Corvol, Julie Beucher, Pierre-Yves Boëlle, et al.
Experimental Dermatology|May 23, 2014
SMAD inhibition attenuates epithelial to mesenchymal transition by primary keratinocytes in vitroDonal O'Kane, Megan V Jackson, Adrien Kissenpfennig, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 28, 2018
Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV<sub>1</sub>Susanna A McColley, Michael W Konstan, Bonnie W Ramsey, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 7, 2019
Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung InfectionsValerie J Waters, Timothy J Kidd, Rafael Canton, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 3, 2019
Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic reviewRanjani Somayaji, Michael D Parkins, Anand Shah, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 4, 2020
Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosisJames F Chmiel, Patrick Flume, Damian G Downey, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|December 8, 2014
Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase)Jill Deacon, Sharif M Abdelghany, Derek J Quinn, et al.
American Journal of Respiratory and Critical Care Medicine|March 28, 2009
Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteersMurali Shyamsundar, Scott T W McKeown, Cecilia M O'Kane, et al.
Scientific Reports|January 17, 2017
Mechanisms of intrinsic resistance and acquired susceptibility of Pseudomonas aeruginosa isolated from cystic fibrosis patients to temocillin, a revived antibioticHussein Chalhoub, Daniel Pletzer, Helge Weingart, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 12, 2019
Antisense oligonucleotide eluforsen is safe and improves respiratory symptoms in F508DEL cystic fibrosisPavel Drevinek, Tacjana Pressler, Marco Cipolli, et al.
Pageof 27

Showing results (191-200 of 270) with videos related to

Sort By:
Pageof 27
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 14, 2011
Ancestral haplotype 8.1 and lung disease severity in European cystic fibrosis patientsHarriet Corvol, Julie Beucher, Pierre-Yves Boëlle, et al.
Experimental Dermatology|May 23, 2014
SMAD inhibition attenuates epithelial to mesenchymal transition by primary keratinocytes in vitroDonal O'Kane, Megan V Jackson, Adrien Kissenpfennig, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 28, 2018
Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV<sub>1</sub>Susanna A McColley, Michael W Konstan, Bonnie W Ramsey, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 7, 2019
Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung InfectionsValerie J Waters, Timothy J Kidd, Rafael Canton, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 3, 2019
Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic reviewRanjani Somayaji, Michael D Parkins, Anand Shah, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 4, 2020
Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosisJames F Chmiel, Patrick Flume, Damian G Downey, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|December 8, 2014
Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase)Jill Deacon, Sharif M Abdelghany, Derek J Quinn, et al.
American Journal of Respiratory and Critical Care Medicine|March 28, 2009
Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteersMurali Shyamsundar, Scott T W McKeown, Cecilia M O'Kane, et al.
Scientific Reports|January 17, 2017
Mechanisms of intrinsic resistance and acquired susceptibility of Pseudomonas aeruginosa isolated from cystic fibrosis patients to temocillin, a revived antibioticHussein Chalhoub, Daniel Pletzer, Helge Weingart, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 12, 2019
Antisense oligonucleotide eluforsen is safe and improves respiratory symptoms in F508DEL cystic fibrosisPavel Drevinek, Tacjana Pressler, Marco Cipolli, et al.
Pageof 27